Login
- Titel:
Combination of Sorafenib and Transarterial Chemoembolization in Selected Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study at Three German Liver Centers.
- Dokumenttyp:
- Journal Article
- Autor(en):
- Koch, Christine; Göller, Markus; Schott, Eckart; Waidmann, Oliver; Op den Winkel, Mark; Paprottka, Philipp; Zangos, Stephan; Vogl, Thomas; Bechstein, Wolf Otto; Zeuzem, Stefan; Kolligs, Frank T; Trojan, Jörg
- Abstract:
- BACKGROUND AND AIMS: Systemic treatment with sorafenib has been the standard of care (SOC) in patients with advanced Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) for more than a decade. TACE has been reported to allow better local tumor control in selected patients with BCLC stage C HCC. METHODS: A retrospective analysis of patients with BCLC stage C HCC that were treated with sorafenib and TACE was conducted; they were compared to BCLC stage C patients treated either with TACE or sorafenib in the same period of time outside a clinical trial. RESULTS: A total of 201 patients with BCLC stage C were identified, who were treated with either sorafenib and TACE (group A; n = 54), sorafenib (group B; n = 82) or TACE (group C; n = 65). No significant difference in baseline characteristics was observed. Time to progression was 7.0 months (95% CI: 4.3-9.7), 4.1 months (95% CI: 3.6-4.7) and 5.0 months (95% CI: 2.9-7.1) in groups A, B and C, respectively, and overall survival was 16.5 months (95% CI: 15.0-18.1), 8.4 months (95% CI: 6.0-10.8) and 10.5 months (95% CI: 7.5-13.6), respectively (group A vs. group B: p < 0.001; group A vs. group C: p = 0.0023). Adverse events of grade 3/4 occurred in 34% of patients in group A. CONCLUSIONS: Although sorafenib is a SOC in patients with BCLC stage C HCC, TACE is frequently used as an additional locoregional treatment in selected patients. This combined approach resulted in a significant overall survival benefit in selected patients, although randomized trials have not yet proven this benefit.
- Zeitschriftentitel:
- Cancers (Basel)
- Jahr:
- 2021
- Band / Volume:
- 13
- Heft / Issue:
- 9
- Volltext / DOI:
- doi:10.3390/cancers13092121
- PubMed:
- http://view.ncbi.nlm.nih.gov/pubmed/33924810
- TUM Einrichtung:
- Professur für Interventionelle Radiologie (Prof. Paprottka)
BibTeX